炎症性疾患に対する生物学的製剤と呼吸器疾患診療の手引き（第2版）
Author:
Affiliation:
1. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
Publisher
Japanese Society of Internal Medicine
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/naika/109/12/109_2531/_pdf
Reference17 articles.
1. 1) Takeuchi T, et al: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194, 2008.
2. 2) Koike T, et al: Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36: 898-906, 2009.
3. 3) Koike T, et al: Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21: 343-351, 2011.
4. 4) Koike T, et al: Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol 24: 390-398, 2014.
5. 5) Komano Y, et al: Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38: 1258-1264, 2011.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3